Medical interventions for addictions in the primary care setting
- PMID: 20305310
Medical interventions for addictions in the primary care setting
Abstract
Primary care physicians treating HIV-infected patients should not be afraid or reluctant to engage in medication-assisted treatment for substance dependence. Effective medications are available for many types of substance addictions, including buprenorphine for opioid dependence, disulfiram for cocaine dependence, bupropion for methamphetamine dependence, and naltrexone for alcohol dependence. Physician use of medications coupled with encouragement to adhere to all aspects of treatment including counseling and other psychosocial interventions can produce substantial rewards in terms of keeping patients involved in their HIV care and improving overall patient health and functioning. This article summarizes a presentation made by R. Douglas Bruce, MD, MA, MSc, at the 12th Annual Clinical Conference for the Ryan White HIV/AIDS Program held in October 2009 in Dallas, Texas. The original presentation is available as a Webcast at www.iasusa.org.
Similar articles
-
Substance use of disorders in HIV-infected patients: impact and new treatment strategies.Top HIV Med. 2004 Jul-Aug;12(3):77-82. Top HIV Med. 2004. PMID: 15310938 Review.
-
Prioritizing primary care in HIV: comorbidity, toxicity, and demography.Top HIV Med. 2006 Dec-2007 Jan;14(5):159-63. Top HIV Med. 2006. PMID: 17237557
-
Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence.Clin Infect Dis. 2005 Sep 15;41(6):891-6. doi: 10.1086/432888. Epub 2005 Aug 10. Clin Infect Dis. 2005. PMID: 16107991 Review.
-
Initial strategies for integrating buprenorphine into HIV care settings in the United States.Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S191-6. doi: 10.1086/508183. Clin Infect Dis. 2006. PMID: 17109306 Review.
-
Substance abuse and HIV infection.Top HIV Med. 2003 Jan-Feb;11(1):20-4. Top HIV Med. 2003. PMID: 12717047
Cited by
-
Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.Br J Clin Pharmacol. 2019 Aug;85(8):1771-1780. doi: 10.1111/bcp.13964. Epub 2019 Jun 5. Br J Clin Pharmacol. 2019. PMID: 30980734 Free PMC article. Clinical Trial.
-
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb. Ther Drug Monit. 2011. PMID: 21544014 Free PMC article. Clinical Trial.
-
Linkage to care for HIV-infected heterosexual men in the United States.Clin Infect Dis. 2011 Jan 15;52 Suppl 2(Suppl 2):S223-30. doi: 10.1093/cid/ciq046. Clin Infect Dis. 2011. PMID: 21342911 Free PMC article. Review.
-
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.Curr Vasc Pharmacol. 2016;14(3):280-7. doi: 10.2174/1570161114666160106151652. Curr Vasc Pharmacol. 2016. PMID: 26733388 Free PMC article.